The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer

Colombo, Carla; Minna, Emanuela; Gargiuli, Chiara; Muzza, Marina; Dugo, Matteo; Cecco, Loris De; Pogliaghi, Gabriele; Tosi, Delfina; Bulfamante, Gaetano; Greco, Angela; Fugazzola, Laura; Borrello, Maria Grazia

doi:10.1186/s13046-020-01757-x

Cited by 31 publications

(34 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTC is known as a general endocrine cancer with excellent prognosis [ 35 , 36 ]. However, unfortunately, several studies have demonstrated that recurrent or metastatic PTC is refractory to most medical treatments [ 8 , 37 , 38 , 39 , 40 ]. Such refractory PTC is usually slothful; however, following anaplasia of the lesion, it becomes undifferentiated cancer that then expands quickly, leading to poor prognosis [ 41 , 42 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer

Yun

Kim

et al. 2022

IJMS

View full text Add to dashboard Cite

Thyroid cancer (TC) includes tumors of follicular cells; it ranges from well differentiated TC (WDTC) with generally favorable prognosis to clinically aggressive poorly differentiated TC (PDTC) and undifferentiated TC (UTC). Papillary thyroid cancer (PTC) is a WDTC and the most common type of thyroid cancer that comprises almost 70–80% of all TC. PTC can present as a solid, cystic, or uneven mass that originates from normal thyroid tissue. Prognosis of PTC is excellent, with an overall 10-year survival rate >90%. However, more than 30% of patients with PTC advance to recurrence or metastasis despite anti-cancer therapy; consequently, systemic therapy is limited, which necessitates expansion of improved clinical approaches. We strived to elucidate genetic distinctions due to patient-derived anti-cancer drug-sensitive or -resistant PTC, which can support in progress novel therapies. Patients with histologically proven PTC were evaluated. PTC cells were gained from drug-sensitive and -resistant patients and were compared using mRNA-Seq. We aimed to assess the in vitro and in vivo synergistic anti-cancer effects of a novel combination therapy in patient-derived refractory PTC. This combination therapy acts synergistically to promote tumor suppression compared with either agent alone. Therefore, genetically altered combination therapy might be a novel therapeutic approach for refractory PTC.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer

Yun

Kim

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…It has to be emphasized that difference in terms of performance (specificity, sensitivity, accuracy) is comparable between these two classes of mining methods (simple and sophisticated). Therefore, in current biomarker research simple solutions such as NTP classifier became popular [ 125 , 126 ]. Moreover, sets of selected markers offer much better performance than single marker, therefore, currently in various studies predictive power have benefited from such multi-marker approach [ 127 ].…”

Section: Applications Of Transcriptome Analysis In Oncologymentioning

confidence: 99%

Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine

Supplitt

Karpiński

Sasiadek

et al. 2021

IJMS

View full text Add to dashboard Cite

Over the last decades, transcriptome profiling emerged as one of the most powerful approaches in oncology, providing prognostic and predictive utility for cancer management. The development of novel technologies, such as revolutionary next-generation sequencing, enables the identification of cancer biomarkers, gene signatures, and their aberrant expression affecting oncogenesis, as well as the discovery of molecular targets for anticancer therapies. Transcriptomics contribute to a change in the holistic understanding of cancer, from histopathological and organic to molecular classifications, opening a more personalized perspective for tumor diagnostics and therapy. The further advancement on transcriptome profiling may allow standardization and cost reduction of its analysis, which will be the next step for transcriptomics to become a canon of contemporary cancer medicine.

show abstract

“…The sodium-iodide symporter (NIS) is a trans-membrane glycoprotein having 13 transmembrane domains that mediates the active uptake of each circulating iodide ion in exchange of 2 intracellular sodium ions by the thyroid gland ( 11 ). It has been found that RAI resistance is related to the abnormal depletion or decreased expression of NIS ( 12 , 13 ). Multiple mechanisms have been identified in connection to altered NIS expression in PTC patients, such as thyroid gland-specific transcription termination factor-1 (TTF1) and paired box gene-8 (PAX8)-mediated induction of thyroid-stimulating hormone (TSH), which in turn modulates NIS transcription ( 14 ).…”

Section: Introductionmentioning

confidence: 99%

Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer

et al. 2022

View full text Add to dashboard Cite

Papillary thyroid cancer (PTC) accounts for about 90% of thyroid cancer. There are approximately 20%–30% of PTC patients showing disease persistence/recurrence and resistance to radioactive iodine (RAI) treatment. For these PTC patients with RAI refractoriness, the prognosis is poor. In this study, we aimed to establish a comprehensive prognostic model covering multiple signatures to increase the predictive accuracy for progression-free survival (PFS) of PTC patients with RAI treatment. The expression profiles of mRNAs and miRNAs as well as the clinical information of PTC patients were extracted from TCGA and GEO databases. A series of bioinformatics methods were successfully applied to filtrate a two-RNA model (IPCEF1 and hsa-mir-486-5p) associated with the prognosis of RAI-therapy. Finally, the RNA-based risk score was calculated based on the Cox coefficient of the individual RNA, which achieved good performances by the time-dependent receiver operating characteristic (tROC) curve and PFS analyses. Furthermore, the predictive power of the nomogram, integrated with the risk score and clinical parameters (age at diagnosis and tumor stage), was assessed by tROC curves. Collectively, our study demonstrated high precision in predicting the RAI response of PTC patients.

show abstract

The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer

Cited by 31 publications

References 57 publications

Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer

Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer

Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine

Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer

Contact Info

Product

Resources

About